Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: FNS who wrote (870)	12/17/1998 11:29:00 AM
From: Douglas Babbin	Read Replies (2) of 965

There is an article in this weeks New England Journal of Medicine describing 6 deaths in patients who had bleeding in their lungs following the administration of ReoPro. All patients presented with heart attacks and congestive heart failure and had an expected mortality rate of 30-40% independent of ReoPro. The idea is the pulmonary edema increases pulmonary blood loss, which may aggravated by ReoPro and other anticoagulant therapies. A response letter by Centocor shows that of almost 450,000 patients who have received ReoPro in the marketplace, 109 cases of pulmonary bleeding has been reported. In the clinical trials conducted by Centocor, 10 out of 5382 patients(.19%) had pulmonary bleeding. These bleeding rates were higher in the earlier trials where doses of heparin were used. From the research I was able to dig up, pulmonary hemmorage is an uncommon complication in patients who receive antithrombotic therapy following heart attacks and subsequent CHF. I've learned it is old news and it is believed it will not have an impact on ReoPro usage. Maybe those more familiar with heart surgery and ReoPro could coment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next